Secnidal

Secnidazole

Method of action: Antiprotozoal

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Secnidal

Quick Facts

Property	Description
Active ingredient	Secnidazole
Form	Oral granules or film-coated tablet
Pharmacological class	Nitroimidazole Antimicrobial
General purpose	Anti-infective agent (combats bacteria and protozoa)
Origin	Synthetic compound

What is Secnidazole and Its Pharmacological Class?

Secnidazole is the sole active pharmaceutical ingredient (INN) found in medications like Secnidal. It is classified as an anti-infective agent and belongs to the official pharmacological class known as Nitroimidazole Antimicrobial. As a synthetic compound, Secnidazole is a derivative of the 5-nitroimidazole structure and is recognized as a second-generation agent within this group, often preferred for its extended half-life. Secnidazole is clinically recognized as an effective antiprotozoal agent used against susceptible microbes. This medication is specifically designed to target and eliminate certain parasitic and anaerobic bacterial organisms.

Composition, Forms, and General Purpose

The medication is a single-ingredient product designed for oral administration, typically manufactured as either oral granules or a film-coated tablet. The oral granules are a key differentiating feature, as they are specifically designed to be mixed with soft foods, such as applesauce, to facilitate easy consumption, especially for patients who experience difficulty swallowing tablets. The broad general purpose of Secnidazole is to eliminate infections caused by susceptible pathogens, specifically anaerobic bacteria and protozoa. For example, it is clinically recognized for use in a single-dose regimen for certain types of bacterial infections. The substance has a specialized mechanism against these organisms, which serves to neutralize a specific range of difficult-to-treat microbes.

How Does Secnidazole Target Infections? (High-Level Action)

Secnidazole achieves its anti-infective effect through broad-spectrum antimicrobial activity that is selectively toxic to anaerobic pathogens. Once administered, the drug is activated within the target cells, leading to a direct and irreversible damage to the microbe's DNA. This action prevents the pathogen from reproducing and ensures its elimination, providing the therapeutic benefit of resolving infections caused by these sensitive anaerobic organisms.

What side effects are possible with Secnidal?

Possible Side Effects and Safety Information

The official safety profile for Secnidal (Secnidazole) is based on regulatory documentation, which classifies adverse reactions by frequency and affected body system. This section details the officially documented effects and major safety constraints.

Officially Documented Adverse Reactions

The following effects are organized by frequency, according to regulatory data:

Classification	System-Organ Class	Example Adverse Reaction
Common (Highest Incidence)	Infections and Infestations	Vulvo-vaginal candidiasis (VVC)
Common	Nervous System Disorders	Headache
Common	Gastrointestinal Disorders	Nausea, Diarrhea, Abdominal pain, Dysgeusia (taste alteration)
Rare	Nervous System Disorders	Dizziness, Coordination disorders (Ataxia), Paresthesia
Rare	Blood System Disorders	Moderate leukopenia (reversible)

Major Regulatory Safety Constraints

Official prescribing information includes specific safety limitations and warnings regarding use, particularly in certain circumstances and populations.

Contraindications: Secnidal is contraindicated in patients with known hypersensitivity to Secnidazole, other formula components, or other nitroimidazole derivatives. It is also contraindicated in patients with Cockayne Syndrome due to the reported risk of severe irreversible hepatotoxicity associated with related medications.
Alcohol Restriction: Consumption of alcoholic beverages or preparations containing ethanol/propylene glycol must be avoided during treatment and for at least 2 days following administration.
Lactation: Breastfeeding is not recommended during treatment and for a period of 96 hours (4 days) after the final dose.
Chronic Use: Regulatory advice specifies that the drug should not be used chronically due to potential long-term safety concerns observed with related compounds.

Overdose and Emergency Response

Overdose Scope and Emergency Actions

The regulatory documentation for Secnidal provides standardized guidance for managing suspected overdosage, focusing on mandated emergency responses and supportive care.

Field	Official Regulatory Statement
Documented overdose presentations	No specific, unique clinical signs of Secnidazole overdosage are formally documented in official prescribing information. Expected manifestations align with exaggerated known adverse reactions such as metallic taste, nausea, or headache.
Emergency-response statements	Seek immediate medical attention for any suspected overdose event. Immediately contact emergency services if the affected individual shows signs of a severe event, such as collapse, seizure, or trouble breathing.
Antidote information	No specific antidote is known for Secnidazole overdose.
Management constraints	Management is restricted to symptomatic and supportive treatment.

Official Overdose Profile

No specific antidote is known for Secnidal overdose, necessitating that management is officially restricted to symptomatic and supportive treatment. When overdosage is suspected, the immediate action required is to seek medical attention for monitoring and clinical assessment. Urgent contact with emergency services is mandated when severe or life-threatening symptoms, such as collapse or an inability to be awakened, are observed, as explicitly stated in government regulatory guidance.

Therapeutic Uses of Secnidal

What Secnidal Treats: Main Uses and Benefits

Secnidal is commonly used to manage specific conditions that involve certain distressing symptoms caused by susceptible bacteria and protozoa. The medication is used in accordance with established therapeutic areas for antimicrobial agents. It is applied in clinical settings where short-term symptomatic assistance is needed to help patients cope more steadily with difficult episodes.

Therapeutic Applications and Symptom Support

Secnidal is commonly used in treating gynecologic and urogenital infections, specifically Bacterial Vaginosis (BV) and Trichomoniasis, conditions presenting with systemic or localized discomfort. It also is relevant in conditions involving protozoal infections like Giardiasis and Amoebiasis. It is applied in situations involving symptoms related to inflammatory or irritative states and organ-specific functional stress.

The application of Secnidazole supports the overall management of symptomatic burden across these specific infectious disease domains.

Its use may assist with reducing the overall symptom load, which contributes to improved day-to-day comfort. It provides supportive relief when symptoms, such as diarrhea, abdominal cramping, abnormal discharge, itching, or burning, become momentarily overwhelming. This supports general well-being during symptomatic phases.

Quick Fact	Description
Support for Urogenital Discomfort	Contributes to improved comfort by addressing symptoms related to inflammatory states like abnormal discharge and genital irritation in BV and Trichomoniasis.
Support for Gastrointestinal Conditions	Is relevant for conditions involving episodic or fluctuating manifestations caused by Giardiasis and Amoebiasis, may assist with managing symptoms such as diarrhea and cramping.

Eligibility and Restrictions for Use

Secnidal is primarily used to treat bacterial vaginosis and trichomoniasis in adults and adolescents aged 12 years and older. Your healthcare provider determines its appropriateness based on your specific condition.

Contraindications and Special Populations

There are specific circumstances and populations where the use of Secnidal (secnidazole) is contraindicated or requires caution. Always inform your doctor about your full medical history and current medications.

Group	Status/Consideration
Allergy	Do not use if you have a known hypersensitivity to secnidazole or other nitroimidazole derivatives (such as metronidazole or tinidazole).
Cockayne Syndrome	Do not use. Use of related drugs in patients with this rare genetic disorder has been associated with severe liver toxicity.
Pregnancy	Use should be based on a careful assessment of risk versus benefit. Other treatments are often preferred, but the decision is up to your doctor.
Breastfeeding	Not recommended during treatment and for at least 96 hours (4 days) after the single dose is taken, due to the drug's long half-life and potential risk to the infant.
Alcohol Consumption	Avoid alcohol and products containing propylene glycol or ethanol during treatment and for at least 48 hours (2 days) after the last dose, as a severe reaction (flushing, nausea, vomiting) may occur.

It is also important to tell your provider about any history of vulvovaginal candidiasis (yeast infection) as this condition may be exacerbated by Secnidal.

What should I know about interactions with other medicines?

The official regulatory profile for Secnidazole outlines specific interaction patterns based on metabolic effects, pharmacodynamic reactions, and formal contraindications.

Interaction Type	Interacting Substance/Condition	Documented Restriction or Outcome
Pharmacodynamic	Alcohol (Ethanol) or Propylene Glycol	Co-administration may cause a disulfiram-like reaction (e.g., severe vomiting, flushing). Avoidance is mandatory.
Metabolic	Oral Anticoagulants (e.g., Warfarin)	Potentiation of the anticoagulant effect, which increases the risk of bleeding, due to decreased hepatic catabolism.
Contraindication	Cockayne Syndrome	A formal contraindication due to the documented risk of severe irreversible hepatotoxicity reported with related medicines.
Efficacy Reduction	Live Attenuated Vaccines	The antibacterial action may decrease the therapeutic efficacy of certain live vaccines (e.g., Cholera or Typhoid Vaccine).

These restrictions are accompanied by specific timing and product-based rules established in official labeling. Consumption of alcoholic beverages and products containing Propylene Glycol must be strictly avoided during therapy and for at least 48 hours following the final dose. The drug is also formally contraindicated for individuals with known Hypersensitivity to Secnidazole or other Nitroimidazole Derivatives. Conversely, the regulatory profile confirms that the medicine may be taken without regard to the timing of meals, as no significant food-based restriction is documented, and no clinically significant interaction was observed with combination Oral Contraceptives.

Mechanism of Action

The mechanism of action proceeds via a two-step cascade: reductive bioactivation of the prodrug and subsequent irreversible damage to the pathogen's genetic material.

Prodrug Activation by Anaerobic Enzymes

Secnidazole is initially inactive; it requires an internal chemical change known as reductive bioactivation to become effective. This process is catalyzed by nitroreductase enzymes found exclusively within the cytoplasm of anaerobic bacteria and protozoa. The low oxygen environment within these cells, characterized by a low redox potential, is essential as it facilitates the one-electron reduction of the drug, which is the crucial step for forming the damaging intermediate molecules. This dependence establishes the mechanism's functional specificity.

Irreversible DNA Damage and Pathogen Elimination

Once activated, the highly unstable nitro-radical intermediates are generated. These intermediates are cytotoxic and immediately attack the pathogen’s essential macromolecules. Their primary action is causing irreversible damage to the microbe's DNA through covalent binding and strand breakage. This extensive damage prevents the pathogen's ability to replicate its genetic material and synthesize vital proteins, resulting in the death of the microbial cell (a bactericidal and protozoacidal effect).

Dosage and Administration Information

Secnidazole administration is characterized by a concise course of therapy. The medicine is strictly for oral administration and is typically available as oral granules in a 2-gram packet or as film-coated tablets in various strengths.

Administration Scope

Feature	Description
Dosing Schedule	The standard regimen for Bacterial Vaginosis and Trichomoniasis is a single 2-gram dose for patients 12 years of age and older. For certain parasitic infections in some regions, multi-day courses (e.g., 1.5 grams daily for five days) may be specified.
Preparation & Timing	Oral granules must be prepared by sprinkling the entire packet onto a soft food, such as applesauce or yogurt. The mixture is to be consumed immediately, entirely, and without chewing, within 30 minutes of preparation, and can be taken without regard to the timing of meals.
Special Conditions	For the treatment of Trichomoniasis, simultaneous administration of the dose to sexual partners is required. Additionally, the consumption of alcohol or preparations containing ethanol must be avoided during treatment and for a minimum of 48 hours (two days) after the single dose is administered.

Connection to the Overall Use Protocol

This protocol establishes the standardized, short-course use of Secnidazole based on a fixed, high-level single dose for its primary indications. The instructions mandate precise preparation steps for the oral granule formulation and impose external constraints, such as the required abstinence from alcohol, defining the full procedure for proper administration.

Recent Clinical Evidence

Evidence for use in Bacterial Vaginosis (BV)

The research examined Bacterial Vaginosis (BV) in women presenting with symptoms, relying on short-term, pivotal Randomized Controlled Trials (RCTs). These studies explored two main outcomes: Clinical Endpoints (measuring symptom resolution) and Microbiological Endpoints (assessing the return to balanced vaginal flora using standardized scoring). Studies described patterns observed in the symptoms of the study populations over short durations, typically assessed at Test of Cure (TOC) visits.

Evidence for use in Trichomoniasis

The research base for Trichomoniasis was explored in trials that included both men and women diagnosed with the infection. Key studies were structured as Phase 3 placebo-controlled RCTs, focusing on parasite eradication and the tracking of signs and symptoms. This research contributes to understanding symptom patterns measured during the study period.

Research into Protozoal Infections (Giardiasis and Amoebiasis)

The evidence for Giardiasis and Amoebiasis is supported by a distinct set of research, often involving older Randomized Studies and Open-Label Comparative Trials. This research examined Parasitological Endpoints (confirmation of parasite absence) and Symptomatic Endpoints (tracking changes in gastrointestinal discomfort). The evidence base is heterogeneous and often relies on older trials compared to the recent regulatory data for BV and Trichomoniasis.

Long-term Follow-up and Durability of Study Outcomes

The majority of the primary study data for all indications focuses on short-term assessments. Long-term data on the recurrence of conditions like BV are not fully established by the core regulatory trials, and research providing extended data on long-term outcomes is still emerging. The follow-up durations were limited in many of the key trials.

Evidence in Specific Patient Populations

Research included adolescents (aged 12 and up) for BV and Trichomoniasis, as well as children for Giardiasis and Amoebiasis. However, data for certain groups remain insufficient. Notably, pregnant women and lactating women were generally excluded from the key registration trials for urogenital infections, meaning the research provides limited context for these specific populations.

What Research Gaps and Uncertainties Remain

Research identified areas where more information is needed. For Giardiasis and Amoebiasis, the evidence quality varies across studies, with many older trials that had modest sample sizes. Data for certain specific subgroups, such as pregnant women or those with immune deficiencies, remain insufficient as these groups were typically not included in the primary research cohorts.

Key Studies & References

Secnidazole response in amoebiasis and giardiasis (WHO EMHJ report)

Frequently Asked Questions (FAQ)

Common questions about Secnidal (FAQ)

Q: How should I dispose of my unused or expired Secnidazole?

Official guidance advises asking a healthcare professional or pharmacist about the proper way to discard the medicine, following local waste regulations. Official documentation may suggest actions like mixing the medicine with an undesirable substance, such as coffee grounds or cat litter, and sealing it in a bag before disposal, particularly if a drug take-back program is unavailable. Always refer to your local rules and consult a professional for clarification.

Q: What should I do if I miss a dose of my Secnidazole?

Secnidal is prescribed as a single, one-time treatment. In situations where the dose is partially missed or completely missed, it is generally recommended to consult a doctor or healthcare professional for guidance. Product information highlights that the full prescribed dose must be administered correctly for the intended effect.

Q: Is it safe to take Secnidazole if I have an allergy to Metronidazole?

Official prescribing information states that Secnidal is contraindicated (should not be used) for patients with a known hypersensitivity or allergy to Secnidazole or to other nitroimidazole derivatives. Because Metronidazole belongs to this same class of antimicrobials, individuals with an allergy to Metronidazole are generally advised to inform their healthcare provider.

Q: How long does it take for Secnidazole to start working?

Studies on the drug’s processing by the body (pharmacokinetics) indicate that Secnidazole begins working once it is absorbed and activated. The drug reaches its maximum concentration in the blood, known as C max, approximately 4 hours after the single dose is administered. This time frame represents when the highest drug levels are achieved in the bloodstream.

Q: What is the shelf-life of Secnidazole?

The official regulatory files support an expiry dating, or shelf-life, of up to 30 months for the product. This expiry is valid when the medication is stored correctly at the recommended controlled room temperature (e.g., 20 C to 25 C). Patients should always refer to the specific expiration date printed on the medication's packaging.

How should Secnidal be stored and disposed of?

Secnidazole (Secnidal) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions up to 30 C allowed. The medication must be kept away from heat, moisture, and direct light, and must not be frozen.

Storage and Disposal Requirements

Requirement Type	Official Stated Rule
Container & Protection	Store in the original, tightly closed container; keep out of the sight and reach of children.
Disposal	Do not keep outdated or unused product; ask a healthcare professional how to discard the medicine according to local pharmaceutical waste regulations.